Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol in advanced gastric cancer
NCT01491217Phase 2Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel + encequidar in gastric cancer (GC), sponsored by Hanmi Pharmaceutical. Primary endpoints: Dose Limiting Toxicity, Overall Response Rate and 2 more. Status: unknown.
02
Drugs
paclitaxel + encequidar
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01491217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491217.